Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 320-323

  Dominguez, Roberto A ^a,c   Kumar, Adarsh M ^a   Cua, William ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Jackson Memorial Hospital ^*

^c JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; ENZYME INHIBITION; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0030036427     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00008     Document Type: Article

References (21)

1. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994; 14:1-4.
2. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1992;32:136-7.
3. Brøsen K, Gram LF, Kragh-Sorensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit 1991;13:177-82.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
5. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;16:125-31.
6. Sinrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
7. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE, The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Pharmacol 1991;32:658P-9P.
8. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-3.
9. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
10. Vandel S, Bertschy G, Bonin B, Nezelof S, Francois TH, Vandel B, Sechter D, Bizourd P. Tricyclic antidepressant plasma levels after fluoxetine addition. Pharmacopsychiatry 1993;25:202-7.
11. Brøsen K, Hansen JG, Nielsen KK, Sinrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44: 349-55.
12. Lemberger L, Bergstrom RF, Wolen RL, Fand NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-9.
13. Kreider MS, Bushnell WD, Wheadon DE. A double-blind, randomized study to provide safety information on switching fluoxetinetreated patients to paroxetine without an intervening washout period. Presented at the Annual ACNP meeting, San Juan, Puerto Rico, December 1992.
14. Lantz RJ, Farid KZ, Koons J, Tenbarge JB, Bopp RJ. Determination of fluoxetine and norfluoxetine in human plasma by capillary gas chromatography with electron-capture detection. J Chromatogr 1993;614:175-9.
15. Brett MA, Dierdorf HD. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;419:438-45.
16. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
17. Zussman B, Fuell D, Quail D. The pharmacodynamics of paroxetine at different dosage levels in adults and elderly patients. Presented at the 18th Congress of the International College of Neuropharmacology, Nice, France, June 1992.
18. Bergstrom RF, Wolen RL, Peyton AL, Goodwin MR, Kasper SC, Barton R, Schwertschlag U, Lemberger L. Pharmacokinetics of R-and S-fluoxetine enantiomers and the effect of P450IID6 activity on their disposition in man. Pharm Res 1992;9:S-306.
19. Sinrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
20. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11:224-5.
21. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993;150:837.